Genetic Signatures (ASX:GSS) Ending Cash Position: A$17.19 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Signatures Ending Cash Position?

Genetic Signatures ASX:GSS -1.49% Ending Cash Position is A$17.19 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Genetic Signatures's Ending Cash Position for the quarter that ended in Dec. 2025 was A$17.19 Mil.

Genetic Signatures's quarterly Ending Cash Position declined from Dec. 2024 (A$40.79 Mil) to Jun. 2025 (A$7.47 Mil) but then increased from Jun. 2025 (A$7.47 Mil) to Dec. 2025 (A$17.19 Mil).

Genetic Signatures's annual Ending Cash Position increased from Jun. 2023 (A$16.35 Mil) to Jun. 2024 (A$36.25 Mil) but then declined from Jun. 2024 (A$36.25 Mil) to Jun. 2025 (A$7.47 Mil).

Genetic Signatures Ending Cash Position Related Terms

Genetic Signatures Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Genetic Signatures's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Signatures Ending Cash Position Chart

Genetic Signatures Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.12 36.90 16.35 36.25 7.47

Genetic Signatures Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.12 36.25 40.79 7.47 17.19

Genetic Signatures Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Genetic Signatures's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=36.252+-28.779
=7.47

Genetic Signatures's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=7.473+9.717
=17.19

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$17.19 Mil mean?
Genetic Signatures (ASX:GSS) has a Ending Cash Position of A$17.19 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Genetic Signatures and its competitors.
Is Genetic Signatures' Ending Cash Position too high?
Genetic Signatures' current Ending Cash Position is A$17.19 Mil.
How does Genetic Signatures' Ending Cash Position compare to TMO and DHR?
Genetic Signatures' Ending Cash Position of A$17.19 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Genetic Signatures and its competitors. Genetic Signatures's current Ending Cash Position is A$17.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Ending Cash Position is A$17.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Ending Cash Position is A$17.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Signatures Business Description

Address 7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.